Rich66
09-13-2010, 02:06 PM
http://www.medicalnewstoday.com/articles/200182.php
ImmuFact(R) IMP321 is a first-in-class antigen-presenting cell (APC) agonist. It is a soluble form of the LAG-3 ("lymphocyte activation gene-3") T cell surface receptor that binds, with high affinity, to MHC ("major histocompatibility complex") class II molecules on APC such as monocytes and dendritic cells. Repeated IMP321 injections lead to strong anti-tumor CD8 T cell responses in cancer patients especially in combination with chemotherapy. <
Until 9 years ago, it was thought that the T cell depletion caused by chemotherapy would make immunotherapy ineffective. However it has now been shown that, on the contrary, the vigorous T cell repopulation following depletion can be directed against the tumor.
ImmuFact(R) IMP321 is a first-in-class antigen-presenting cell (APC) agonist. It is a soluble form of the LAG-3 ("lymphocyte activation gene-3") T cell surface receptor that binds, with high affinity, to MHC ("major histocompatibility complex") class II molecules on APC such as monocytes and dendritic cells. Repeated IMP321 injections lead to strong anti-tumor CD8 T cell responses in cancer patients especially in combination with chemotherapy. <
Until 9 years ago, it was thought that the T cell depletion caused by chemotherapy would make immunotherapy ineffective. However it has now been shown that, on the contrary, the vigorous T cell repopulation following depletion can be directed against the tumor.